Valuation: Roche Holding AG

Market Cap 283B 347B 305B 260B 489B 33,566B 496B 3,371B 1,317B 16,441B 1,305B 1,277B 56,819B P/E 2026 *
19.2x
P/E 2027 * 17.6x
Enterprise Value 294B 360B 316B 270B 507B 34,807B 514B 3,496B 1,365B 17,049B 1,353B 1,324B 58,919B EV / Sales 2026 *
4.69x
EV / Sales 2027 * 4.39x
Free-Float
88.78%
Yield 2026 *
2.82%
Yield 2027 * 2.88%
1 day-1.35%
Current month+3.91%
6 months-1.33%
Current year+2.04%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 347B
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
-0.16%-2.04%-1.01%-33.78% 140B
Average +0.13%+0.41%+21.98%+45.28% 381.82B
Weighted average by Cap. +0.46%+1.35%+34.39%+78.45%

Financials

2026 *2027 *
Net sales 62.65B 76.75B 67.33B 57.47B 108B 7,419B 110B 745B 291B 3,634B 288B 282B 12,558B 65.41B 80.14B 70.31B 60B 113B 7,746B 114B 778B 304B 3,794B 301B 295B 13,112B
Net income 14.67B 17.97B 15.77B 13.46B 25.31B 1,737B 25.66B 174B 68.15B 851B 67.52B 66.08B 2,941B 16.33B 20.01B 17.55B 14.98B 28.17B 1,934B 28.57B 194B 75.86B 947B 75.16B 73.56B 3,274B
Net Debt 10.48B 12.84B 11.26B 9.61B 18.08B 1,241B 18.33B 125B 48.68B 608B 48.23B 47.2B 2,101B 3.75B 4.59B 4.03B 3.44B 6.47B 444B 6.56B 44.59B 17.41B 217B 17.25B 16.89B 751B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA